Advertisement

Management of Heart Failure

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Heart failure (HF), unlike coronary heart disease (CHD), has no territorial boundaries.
  • The world faces an epidemic of heart failure. The plague of HF is common in developed and in developing countries.

  • Although treatment strategies have improved considerably over the past decade, improvement in outcomes remain modest and the incidence of HF is increasing. Some of this increase is owing to an aging population in all countries.

  • In the United States about 5 million individuals have HF. In addition, more than half a million patients are diagnosed with a first episode of HF each year, and approximately 80% of these are over age 65.

  • In the United States, HF causes more than 300,000 deaths annually (1) over the past 10 yr hospitalizations for HF have risen from approx 550,000 to approx 900,000 (2). The cost worldwide is astronomic: in the United States more Medicare dollars are spent on the management of HF than for any other diagnosis (3) and this cost is estimated to be $28 billion annually.

Keywords

Heart Failure Constrictive Pericarditis Isosorbide Dinitrate Arrhythmogenic Right Ventricular Dysplasia Severe Chronic Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Connell JB, Bristow M. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1999;13:S107.Google Scholar
  2. 2.
    Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey. Am Heart J 1999; 137:352.PubMedCrossRefGoogle Scholar
  3. 3.
    Hunt SH, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2001;38:2101.PubMedCrossRefGoogle Scholar
  4. 4.
    Hunt S A, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46: 1116–1143.CrossRefGoogle Scholar
  5. 5.
    Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-typenatriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson Tang WH, Francis GS. The year in heart failure. J Am Coll Cardiol 2005;46:2125–2133.CrossRefGoogle Scholar
  7. 7.
    Packer M. Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure?: The price we pay for interfering with evolution. J Am Coll Cardiol 1985;6:171.Google Scholar
  8. 8.
    Packer M, Lee WH, Yushak M, et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847.PubMedCrossRefGoogle Scholar
  9. 9.
    CONSENSUS: Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 1987;316:1429.CrossRefGoogle Scholar
  10. 10.
    A-HeFT: Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.PubMedCrossRefGoogle Scholar
  11. 11.
    Cohn JN, Archibald DG, Francis GS, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: Influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987;75(JV):IV–49.Google Scholar
  12. 12.
    Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314: 1547.PubMedCrossRefGoogle Scholar
  13. 13.
    V-HeFTII: Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303.PubMedCrossRefGoogle Scholar
  14. 14.
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293.CrossRefGoogle Scholar
  15. 15.
    Furberg CD, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol 1985;55:1110.PubMedCrossRefGoogle Scholar
  16. 16.
    Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol 1988;62:41A.PubMedCrossRefGoogle Scholar
  17. 17.
    Agostoni PG, De Gasare N, Doria E, et al. Afterload reduction: A comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J 1986;55:391.PubMedCrossRefGoogle Scholar
  18. 18.
    SAVE: Pfeffer MA, Braunwald E, Moye LA, et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669.PubMedCrossRefGoogle Scholar
  19. 19.
    AIRE: Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821.Google Scholar
  20. 20.
    Cleland JGF, Dargie HJ, Mc Alpine H, et al. Severe hypotension after first dose of enalapril in heart failure. BMJ 1985;291:1309.PubMedCrossRefGoogle Scholar
  21. 21.
    Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: Amulticenter study. J Am Coll Cardiol 2000;36:2090.PubMedCrossRefGoogle Scholar
  22. 22.
    ATLAS Study Group. Packer M, Poole-Wilson PA, Armstrong P, et al. Comparative effects of low and high doses of angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312.PubMedGoogle Scholar
  23. 23.
    CHARM: Granger CB, McMurray JJV, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM-alternative trial. Lancet 2003;362: 772–776.PubMedCrossRefGoogle Scholar
  24. 24.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.PubMedCrossRefGoogle Scholar
  25. 25.
    Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 1981;64:499.PubMedGoogle Scholar
  26. 26.
    PRAISE: Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. For the Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107.PubMedCrossRefGoogle Scholar
  27. 27.
    Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;336:29.CrossRefGoogle Scholar
  28. 28.
    RALES: Pitt B, Zannad F, Remme WJ, et al. for the Randomized Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709.PubMedCrossRefGoogle Scholar
  29. 28a.
    Stevens LA, Coresh J, Green T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.PubMedCrossRefGoogle Scholar
  30. 29.
    Hass GJ, Abraham WT. The challenge of heart failure. J Am Coll Cardiol 2005;46:2052–2053.CrossRefGoogle Scholar
  31. 30.
    Khan M Gabriel, Goodwin JF. Cardiomyopathy. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.Google Scholar
  32. 31.
    Bristow MR, Kantrowitz NE, Ginsburg R, et al. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985;17:41.PubMedCrossRefGoogle Scholar
  33. 32.
    Waagstein F, Hjalmarson A, Swedberg K, et al. Beta-blockers in dilated cardiomyopathies: They work. Eur Heart J 1993;173(Suppl A).Google Scholar
  34. 33.
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349.PubMedCrossRefGoogle Scholar
  35. 34.
    CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. Lancet 2001;357:1385.CrossRefGoogle Scholar
  36. 35.
    Packer M, Coats JS, Fowler MB, et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651.PubMedCrossRefGoogle Scholar
  37. 36.
    Waagstein F, Bristow MR, Swedberg K, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342:1441.PubMedCrossRefGoogle Scholar
  38. 37.
    MERIT/HF: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 2000;283:1295.CrossRefGoogle Scholar
  39. 38.
    CIBIS-II: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Arandomized trial. Lancet 1999;353: 9–13.CrossRefGoogle Scholar
  40. 39.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525.CrossRefGoogle Scholar
  41. 40.
    Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.PubMedCrossRefGoogle Scholar
  42. 41.
    Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980;303:1443.PubMedCrossRefGoogle Scholar
  43. 42.
    Gheorghiade M, St Clair J, St Clair C, et al. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987;9:849.PubMedGoogle Scholar
  44. 43.
    Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: Placebocontrolled trial in outpatients. BMJ 1977;1:749.PubMedGoogle Scholar
  45. 44.
    Packer M, Gheorghiade M, Young JB, et al. for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1.PubMedCrossRefGoogle Scholar
  46. 45.
    Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A.CrossRefGoogle Scholar
  47. 46.
    Schenck-Gustafsson K, Jublin-Dannfelt A, Dahlquist R. Renal function and digoxin clearance during quinidine therapy. Clin Physiol 1982;2:401.PubMedGoogle Scholar
  48. 47.
    Zatuchni J. Verapamil-digoxin interaction. Am Heart J 1984;108:412.PubMedCrossRefGoogle Scholar
  49. 48.
    Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol 1985;5: 82A.PubMedCrossRefGoogle Scholar
  50. 49.
    Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Circulation 1990;82:1744.Google Scholar
  51. 50.
    Mikulic E, Cohn JN, Franciosa JA. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circulation 1977;56:528.PubMedGoogle Scholar
  52. 51.
    Little WC. Enhanced load dependence of relaxation in heart failure: Clinical implications. Circulation 1992;85:2326.PubMedGoogle Scholar
  53. 52.
    Little WC, Cheng CP. Diastolic dysfunction. Cardiol Rev 1998;6:231.PubMedCrossRefGoogle Scholar
  54. 53.
    Meier-Ewert HK, Gaasch WH. What is diastolic heart failure and how do we treat it? ACC Curr J Rev Nov/Dec:52, 2001.Google Scholar

Suggested Reading

  1. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.PubMedCrossRefGoogle Scholar
  2. Bhatia RS, Tu JV, Lee DS. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260–269.PubMedCrossRefGoogle Scholar
  3. Davis BR, Piller LB, Cutler JA, et al. for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006;113:2201–2210.PubMedCrossRefGoogle Scholar
  4. de Goma EM, Vagelos RH, Fowler MB. Emerging therapies for the management of decompensated heart failure. J Am Coll Cardiol 2006;48:2397–2409.CrossRefGoogle Scholar
  5. Gheorghiade M, Dirk J. van Veldhuisen, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556–2564.PubMedCrossRefGoogle Scholar
  6. Greenberg B, Mehra MR. All patients with heart failure and intraventricular conduction defect or dyssynchrony should not receive cardiac resynchronization therapy. Circulation 2006;114:2685–2691.PubMedCrossRefGoogle Scholar
  7. Hass GJ, Abraham WT. The challenge of heart failure. J Am Coll Cardiol 2005;46:2052–2053.CrossRefGoogle Scholar
  8. Jhund P, McMurray JV. Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor?: Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 2006;113:2566–2568.PubMedCrossRefGoogle Scholar
  9. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485–2489.PubMedCrossRefGoogle Scholar
  10. Owan TE, Hodge DO, Herges RM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.PubMedCrossRefGoogle Scholar
  11. Pfeffer MA. Editorial Comment. Blood pressure in heart failure: A love-hate relationship. J Am Coll Cardiol 2007;49:40–42.PubMedCrossRefGoogle Scholar
  12. Ramasubbu K, Mann DL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2006; 47:342–344.PubMedCrossRefGoogle Scholar
  13. Remme WJ, Torp-Pedersen C, Cleland JGF, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: research from COMET. J Am Coll Cardiol 2007;49:963–971.PubMedCrossRefGoogle Scholar
  14. Scirica BM, Morrow DA, Cannon CP, et al. for the PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 STUDY. J Am Coll Cardiol 2006;47:2326–2331.PubMedCrossRefGoogle Scholar
  15. Stevens LA, Coresh J, Greene T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.PubMedCrossRefGoogle Scholar
  16. Takemoto Y, Hozumi T, Sugioka K, et al. Beta-blocker therapy induces ventricular resynchronization in dilated cardiomyopathy with Narrow QRS complex. J Am Coll Cardiol 2007;49:778–783.PubMedCrossRefGoogle Scholar
  17. Tang WH, Francis GS. The year in heart failure. J Am Coll Cardiol 2006;48:2575–2583.PubMedCrossRefGoogle Scholar
  18. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations